NCT06216054View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
Tardive DyskinesiaHuntington Disease
Interventions
DRUG

LPM3770164 sustained release tablet

administrated orally

DRUG

LPM3770164 sustained release tablet simulant

administrated orally

Trial Locations (1)

Unknown

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT06216054 - Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects | Biotech Hunter | Biotech Hunter